GlassScriptPhysician profile
Kim D Colter
NPI 1336112846
$2,373.18
in general payments reported to CMS, 2019-2025
28 companies · $32.40 in 2025
The $32.40 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $219 · 2021: $702 · 2022: $426 · 2023: $406 · 2024: $432 · 2025: $32.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.44 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $283.89 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $178.37 | 2019-2023 | Emgality, Jardiance, Trulicity |
| Amgen INC. | $163.59 | 2019-2023 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $159.80 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $141.14 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $106.20 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $100.09 | 2023-2024 | Gemtesa |
| Abbott Laboratories | $92.98 | 2023-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $84.46 | 2021-2022 | |
| Esperion Therapeutics, INC. | $75.12 | 2020-2021 | |
| Exact Sciences Corporation | $67.01 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $65.91 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $61.66 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $60.98 | 2021-2024 | Austedo Xr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $59.55 | 2023-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $57.77 | 2021-2024 | Breztri, Farxiga |
| Edwards Lifesciences Corporation | $50.98 | 2020-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbvie INC. | $42.84 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $41.76 | 2022-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.34 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.86 | 2022-2024 | |
| Pfizer INC. | $22.64 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $16.66 | 2021 | |
| Averitas Pharma INC. | $16.29 | 2024 | Qutenza |
| Eisai INC. | $14.57 | 2021 | |
| Lundbeck LLC | $13.58 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Colter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.